Cangrelor at PCI Cuts Ischemic Events vs ClopidogrelCangrelor at PCI Cuts Ischemic Events vs Clopidogrel

Not yet approved by regulators anywhere, the novel P2Y12-receptor antagonist reduced the risk of 48-hour ischemic events compared with the older antiplatelet. Heartwire
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news